Endothelial dysfunction: Clinical strategies for treating oxidant stress

被引:74
作者
Fenster, BE [1 ]
Tsao, PS [1 ]
Rockson, SG [1 ]
机构
[1] Stanford Univ, Div Cardiovasc Med, Sch Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA
关键词
D O I
10.1016/S0002-8703(02)94796-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A growing body of evidence has demonstrated that oxidants play a critical role in the pathogenesis of endothelial dysfunction. Pathologic processes fundamental to development and progression of endothelial dysfunction such as the oxidation of LDL, the loss of bioavailable nitric oxide, and the vascular inflammatory response are all modulated by oxidant stress. Therapeutic strategies to reverse endothelial dysfunction have begun to focus on agents with the ability to ameliorate oxidant stress. Methods Preclinical and clinical studies evaluating the actions of antioxidants as well as traditional cardiovascular therapies in ameliorating oxidative stress and endothelial dysfunction were reviewed through the use of a MEDLINE search of English language articles published between the years of 1992 and 2002. Results Antioxidants appear to be an attractive candidate therapy, yet despite compelling preclinical evidence supporting their benefits, efforts to validate the use of vitamins C and E in a clinical setting have been conflicting. In contrast, conventional cardiovascular therapies such as ACE inhibitors, statins, insulin-sensitizing agents, and estrogens have been shown to alleviate endothelial dysfunction, often independent of their effects on systemic disease processes. Conclusions These agents restore endothelial function through their salutary effects on pathologic vascular oxidative processes.
引用
收藏
页码:218 / 226
页数:9
相关论文
共 49 条
[1]   Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease [J].
Adams, MR ;
McCredie, R ;
Jessup, W ;
Robinson, J ;
Sullivan, D ;
Celermajer, DS .
ATHEROSCLEROSIS, 1997, 129 (02) :261-269
[2]   Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes:: Evidence of an antiinflammatory action? [J].
Aljada, A ;
Garg, R ;
Ghanim, H ;
Mohanty, P ;
Hamouda, W ;
Assian, E ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (07) :3250-3256
[3]   Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) [J].
Anderson, TJ ;
Elstein, E ;
Haber, H ;
Charbonneau, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :60-66
[4]   Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes [J].
Avena, R ;
Mitchell, ME ;
Nylen, ES ;
Curry, KM ;
Sidawy, AN .
JOURNAL OF VASCULAR SURGERY, 1998, 28 (06) :1024-1031
[5]   Expression of NADH/NADPH oxidase p22phox in human coronary arteries [J].
Azumi, H ;
Inoue, N ;
Takeshita, S ;
Rikitake, Y ;
Kawashima, S ;
Hayashi, Y ;
Itoh, H ;
Yokoyama, M .
CIRCULATION, 1999, 100 (14) :1494-1498
[6]   Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].
Böger, RH ;
Bode-Böger, SM ;
Szuba, A ;
Tsao, PS ;
Chan, JR ;
Tangphao, O ;
Blaschke, TF ;
Cooke, JP .
CIRCULATION, 1998, 98 (18) :1842-1847
[7]   Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease [J].
Böger, RH ;
Bode-Böger, SM ;
Thiele, W ;
Creutzig, A ;
Alexander, K ;
Fröhlich, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) :1336-1344
[8]   VITAMIN-E IN HUMAN LOW-DENSITY-LIPOPROTEIN - WHEN AND HOW THIS ANTIOXIDANT BECOMES A PROOXIDANT [J].
BOWRY, VW ;
INGOLD, KU ;
STOCKER, R .
BIOCHEMICAL JOURNAL, 1992, 288 :341-344
[9]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[10]   Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension [J].
Butler, R ;
Morris, AD ;
Belch, JJF ;
Hill, A ;
Struthers, AD .
HYPERTENSION, 2000, 35 (03) :746-751